An Observational Study on the Obesity and Metabolic Status of Psoriasis Patients

Kim, Cho Rok; Lee, Joo Heung

doi:10.5021/ad.2013.25.4.440

Cited by 22 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Kim and Lee15 reported no statistical difference in BMI between the patients with psoriasis and a control group in one study of a Korean population. This implies that further research is necessary to clarify the association between obesity and psoriasis in the Korean population.…”

Section: Discussionmentioning

confidence: 95%

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundPsoriasis is an immune-mediated, chronic inflammatory disease affecting multiple aspects of patients' lives. Its epidemiology varies regionally; however, nationwide epidemiologic data on psoriasis depicting profile of Korean patients has not been available to date.ObjectiveTo understand nationwide epidemiologic characteristics and clinical features of adult patients with psoriasis visited university hospitals in Korea.MethodsThis multicenter, non-interventional, cross-sectional study recruited 1,278 adult patients with psoriasis across 25 centers in Korea in 2013. Various clinical data including PASI, BSA, DLQI, SF-36 and PASE were collected.ResultsA total of 1,260 patients completed the study (male:female=1.47:1). The mean age was 47.0 years with a distribution mostly in the 50s (24.9%). Early onset (<40 years) of psoriasis accounted for 53.9% of patients. The mean disease duration was 109.2 months; mean body mass index was 23.9 kg/m2; and 12.7% of patients had a family history of psoriasis. Plaque and guttate types of psoriasis accounted for 85.8% and 8.4%, respectively. Patients with PASI ≥10 accounted for 24.9%; patients with body surface area ≥10 were 45.9%. Patients with DLQI ≥6 accounted for 78.8%. Between PASI <10 and PASI ≥10 groups, significant difference was noted in age at diagnosis, disease duration, blood pressure, waist circumference of female, and treatment experiences with phototherapy, systemic agents, and biologics.ConclusionThis was the first nationwide epidemiologic study of patients with psoriasis in Korea and provides an overview of the epidemiologic characteristics and clinical profiles of this patient population.

show abstract

Section: Discussionmentioning

confidence: 95%

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since 1987, numerous studies have been conducted to study DL in Ps [1,2,5,6,7,8,9,10,11,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]. The results vary since they are based on heterogeneous populations, with or without associated comorbidities, and do not always take into account prescribed medications that can alter the lipid profile or liver function tests [29,30,31,32,33,34,35].…”

Section: Discussionmentioning

confidence: 99%

“…DM type 2 was identified when subjects had a fasting blood glucose (at least 8 h) ≥126 mg/dl or if they had a medical history of it or took antidiabetic medications. For this study, we defined DL according to the guidelines set by the Third Report of Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III) [9]. Patients were coded as suffering from DL if the results in serum tests were TG >150 mg/dl (>1.71 mmol/l), LDL cholesterol >130 mg/dl (>3.36 mmol/l), total cholesterol (TCh) >200 mg/dl (>5.2 mmol/l) and high-density lipoprotein (HDL) cholesterol <40 mg/dl (<1.03 mmol/l).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis Vulgaris with or without Arthritis and Independent of Disease Severity or Duration Is a Risk Factor for Hypercholesterolemia

Santos‐Juanes

Coto-Segura²,

Fernández‐Vega³

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: Psoriasis (Ps) has been associated with an increased incidence of cardiovascular disease. Interesting epidemiological evidence suggests associations between Ps and dyslipidemia (DL), a well-established risk factor for cardiovascular disease. Objective: This study aimed to investigate the association between Ps and multiple measurements of DL, which include levels of triglycerides (TGs), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and total cholesterol (TCh). We also studied the relationship between DL and disease duration. Methods: A prospective hospital-based study was conducted. A total of 661 Caucasian patients with chronic plaque Ps and 661 sex- and age-matched controls were enrolled. Results: Multivariate analysis showed that in psoriatic patients the odds ratio (OR) of TCh >200 mg/dl was 1.406 (95% confidence interval 1.115-1.173), the OR of LDL cholesterol >130 mg/dl was 1.375 (95% confidence interval 1.088-1.738), the OR of HDL cholesterol <40 mg/dl was 0.881 (95% confidence interval 0.599-1.297), and the OR of TGs >150 mg/dl was 1.041 (95% confidence interval 0.783-1.385). We did not find a relationship between lipid levels and disease duration. Conclusion: Based on our population Ps is associated with alterations in TCh and LDL cholesterol, but not in TGs and HDL cholesterol, when ATP III panel levels are used. These alterations are not related to disease duration.

show abstract

“…It is worth noting that obesity is an important risk factor for this autoimmune disease and may affect the pharmacokinetics of the drug. This is an important element in the choice of therapeutic strategy . Recent studies more and more often indicate cellular and molecular psoriatic mediators .…”

Section: Introductionmentioning

confidence: 99%

Are new variants of psoriasis therapy (IL‐17 inhibitors) safe?

Wcisło‐Dziadecka

Kaźmierczak²,

Grabarek³

et al. 2019

Int J Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional methods of psoriasis treatment (phototherapy, methotrexate, retinoids, cyclosporine A) fail, we reach for the following biopharmaceuticals – infliximab, etanercept, adalimumab, or ustekinumab. However, genetic engineering progress discovers new possibilities – the pending clinical trials involve IL‐17, IL‐23 antagonists, PDE4 and ‐3 and ‐1. Psoriasis etiopathogenesis mainly involves the IL‐17A, IL‐17F, and IL‐17A/F subtypes, which affect the keratinocytes. The biological therapy molecularly oriented with the antagonists of interleukin 17 is based mainly on the influence onto the cytokine in the manner that prevents it from binding with the receptor. Three biopharmaceuticals are currently under third phase studies: two fully humanized antibodies neutralizing IL‐17 – ixekizumab and secukinumab, and one human monoclonal antibody, brodalumab. The below work will be devoted to the analysis of possible undesirable symptoms, which were observed during the studies. We will try to review the latest literature concerning the most important clinical trials conducted in many centers.

show abstract

An Observational Study on the Obesity and Metabolic Status of Psoriasis Patients

Cited by 22 publications

References 15 publications

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

Psoriasis Vulgaris with or without Arthritis and Independent of Disease Severity or Duration Is a Risk Factor for Hypercholesterolemia

Are new variants of psoriasis therapy (IL‐17 inhibitors) safe?

Contact Info

Product

Resources

About